title: Effect of endostar combined with cisplatin on expression of VEGF and Sema3A of Lewis lung cancer rats.
abstract: OBJECTIVE
  To evaluate the therapeutic effect of endostar (ED) combined with cisplatin(DDP) on model of C57BL/6 rats, and to further investigate the inhibiting mechanism of endostar from tumor angiogenesis.
  
  
  METHODS
  Lewis lung cancer cells were inoculated in C57BL/6 mouse, then the mouse were randomized into control group (group A), ED (group B), DDP (group C) and ED/DDP (group D). They were treated according to the plan. And the expressions of VEGF and Sema3A were evaluated by immunhistochemisty.
  
  
  RESULTS
  The weight of tumor increased in group A and B. It was decreased in group C and D. The tumor volume was increased in all the 4 groups. The VEGF expression of group D was obviously lower than the other group 3, but the Sema3A expressed of group D was significantly strengthener than the other group 3. The VEGF expression of group B and group D were obviously low especially in the 4th-8th days. Pearson correlated analysis showed that the expression VEGF and Sema3A were negatively correlated (r=-0.72, P<0.05).
  
  
  CONCLUSIONS
  ED combined with DDP could control the tumor growth effectively, and avoid weight loss. ED could reduce VEGF expression, and enhance Sema3A expression. Tumor vessel presents transient normalization. It is easy for DDP perfusion, and to kill tumor cells.
authors: Master of Respiratory Medicine, Hebei Northern College, Zhangjiakou 075000, Hebei, China.
authors: Ping
authors: P
authors: Feng
authors: Zhi-Lin
authors: ZL
authors: Zhang
authors: Zhi-Hua
authors: ZH
authors: Zhang
authors: Xiu-Long
authors: XL
authors: Zhang
authors: Feng
authors: F
authors: Xiang
authors: Jian-Hua
authors: JH
authors: Tang
authors: Bao-Li
authors: BL
authors: Xiang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology*; D043169:Endostatins / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D051381:Rats; D011994:Recombinant Proteins; D040121:Semaphorin-3A / Q000096:biosynthesis*; D042461:Vascular Endothelial Growth Factor A
chemical_list: D000970:Antineoplastic Agents; D043169:Endostatins; D011994:Recombinant Proteins; C488217:Sema3a protein, mouse; D040121:Semaphorin-3A; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse; C522911:endostar protein; D002945:Cisplatin